Renaissance Technologies LLC Increases Stake in Glaukos Co. (NYSE:GKOS)

Renaissance Technologies LLC increased its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 30.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,600 shares of the medical instruments supplier's stock after acquiring an additional 11,608 shares during the quarter. Renaissance Technologies LLC owned about 0.09% of Glaukos worth $7,437,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. IFP Advisors Inc acquired a new position in Glaukos in the 4th quarter worth $43,000. Asset Planning Inc acquired a new position in Glaukos during the 4th quarter worth approximately $90,000. Picton Mahoney Asset Management bought a new stake in shares of Glaukos in the fourth quarter worth $125,000. SBI Securities Co. Ltd. acquired a new position in shares of Glaukos during the 4th quarter worth about $153,000. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Glaukos by 275.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock valued at $164,000 after acquiring an additional 807 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares in the company, valued at $5,708,568.04. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Mizuho decreased their target price on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Needham & Company LLC lifted their price objective on shares of Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Piper Sandler lowered their target price on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 15th. Truist Financial reduced their price target on Glaukos from $185.00 to $140.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Finally, Stifel Nicolaus lifted their price objective on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, December 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Glaukos currently has an average rating of "Moderate Buy" and an average price target of $156.17.

Glaukos Trading Up 1.9 %

NYSE GKOS traded up $1.76 on Thursday, reaching $94.37. The company had a trading volume of 152,238 shares, compared to its average volume of 640,987. The firm has a market cap of $5.34 billion, a price-to-earnings ratio of -32.83 and a beta of 0.88. The business has a 50 day moving average of $104.65 and a two-hundred day moving average of $130.56. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a fifty-two week low of $77.91 and a fifty-two week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $105.50 million for the quarter, compared to analysts' expectations of $100.72 million. Analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.